Trial Profile
Phase 1/2 Randomized Trial Combination of Ruxolitinib and Peg-interferon Alpha-2a in Patients With Primary Myelofibrosis Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms RUXOPEG
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 26 Jul 2022 Status changed from active, no longer recruiting to completed.
- 19 Jul 2021 Planned End Date changed from 1 Dec 2021 to 31 Dec 2021.